Omalizumab, Remibrutinib Show Similar Early Hives Relief

A post hoc indirect analysis found the two treatments produced comparable placebo-adjusted improvements in chronic spontaneous urticaria over 14 days.

Updated on Nov. 14, 2026 in Allergies

Three unlabeled amber glass vials and a clear syringe on a brushed steel tray in a bright clinical lab setting.
Omalizumab and remibrutinib produced similar early hives relief over 14 days in an indirect analysis funded by Genentech, presented at the ACAAI 2026 meeting in Phoenix. AI Illustration. Upload story photo >

A post hoc indirect analysis presented at the ACAAI 2026 Annual Scientific Meeting in Phoenix found omalizumab and remibrutinib showed similar early improvements in chronic spontaneous urticaria over the first 14 days of treatment. The analysis pooled phase 3 data, and Genentech funded the work, with three of its six authors employed by the company.

Why it matters

Chronic spontaneous urticaria, which causes recurring hives, has several treatment options, and clinicians compare them on how quickly symptoms ease. Because the comparison was indirect and unmatched, the findings suggest similarity in early response but cannot establish that one drug works better than the other.

The analysis compared placebo-adjusted daily urticaria activity scores across pooled trials, with omalizumab's week 2 response at 39% versus 6% for placebo. Because the comparison was unmatched, the reported similarity between the two drugs does not establish that either is superior.

The players

Genentech

Genentech is a biotechnology company and member of the Roche Group that develops and markets immunology and dermatology therapies, including omalizumab.

American College of Allergy, Asthma and Immunology (ACAAI)

The ACAAI is a professional medical society of allergists, asthma specialists and immunologists that holds an annual scientific meeting to share clinical research.

The details

Researchers compared daily urticaria activity scores over the first 14 days using unmatched comparisons and two-sample t tests on placebo-adjusted differences. Week 1 response was 6% for omalizumab versus 2% for placebo, and complete response by week 2 was 13% versus 3%. Genentech funded the analysis, and three of its six authors are Genentech employees.

Timeline

  1. November 12-16, 2026: ACAAI 2026 Annual Scientific Meeting held in Phoenix, where the analysis was presented.

  2. Week 1 of treatment: omalizumab response reached 6% versus 2% for placebo.

  3. Week 2 of treatment: omalizumab response reached 39% versus 6% for placebo.

Health Landscape

The comparison draws on the phase 3 ASTERIA I/II and REMIX-1/REMIX-2 programs, which established omalizumab and remibrutinib as separate treatments for chronic spontaneous urticaria. This indirect analysis of those programs adds early-response data but still leaves head-to-head evidence unresolved for clinicians choosing among options in the United States.

For people living with chronic hives, the analysis suggests both treatments may ease symptoms within the first two weeks, though the comparison is indirect. Patients weighing options should discuss treatment choice, including side effects and cost, with their clinician rather than relying on this early-response finding alone.

The takeaway

Early symptom improvement with omalizumab and remibrutinib looked similar in this indirect comparison, but head-to-head trials are needed before drawing firm conclusions about which works better.

Further reading

For more on how allergy treatments are evaluated, explore Allergies coverage across the United States.